SNT 2.86% 3.4¢ syntara limited

Gilead in $470 million NASH deal, page-2

  1. 35,748 Posts.
    lightbulb Created with Sketch. 554
    Enanta moved into the NASH race last week as well.

    They've already had big success bringing in cash on their Hep C deal with AbbVie.

    Now they're moving their second tier to select & advance a preclinical NASH candidate viewing the same kind of commercial opportunity as Hep C offered.

    So far they are up to around $230M in cash payments & milestones received on Hep C.
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
(20min delay)
Last
3.4¢
Change
-0.001(2.86%)
Mkt cap ! $43.87M
Open High Low Value Volume
3.5¢ 3.5¢ 3.4¢ $14.00K 402.4K

Buyers (Bids)

No. Vol. Price($)
3 440288 3.4¢
 

Sellers (Offers)

Price($) Vol. No.
3.6¢ 374403 3
View Market Depth
Last trade - 15.50pm 30/08/2024 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.